Level A Evidence
4 Treatment Options Available
Blood Cancer Treatment
Leukemia, Lymphoma & Myeloma: Chemo, CAR-T & Transplant
Hematologic cancers require specialized multidisciplinary care including advanced diagnostics, targeted therapies, and cellular therapies. China offers comprehensive leukemia/lymphoma programs with access to CAR-T cell therapy and allogeneic stem cell transplantation at significantly lower costs than Western countries.
Condition Overview
Conditions We Treat
Acute Leukemia (AML/ALL)Lymphoma (Hodgkin/NHL)Multiple MyelomaMDS/MPNStem Cell Transplant
Core Technologies
CAR-T cell therapy | Allogeneic stem cell transplant | Autologous transplant | Targeted therapy (BTK, BCL-2) | Immunomodulatory drugs
Идеальные кандидаты
- •Need for allogeneic stem cell transplant
- •CAR-T cell therapy for relapsed lymphoma/leukemia
- •Complex acute leukemia requiring intensive therapy
- •Relapsed/refractory multiple myeloma
- •Access to novel clinical trials
Comprehensive hematology centers with transplant units
Рассмотрите местные варианты
- •Standard chemotherapy protocols for lymphoma
- •Maintenance therapy phase
- •Routine surveillance after remission
- •Cases with established local hematologist
Standard phases with good local oncology support
Evidence: Partner centers >300 transplants/year; CAR-T response rate 70-80% for B-ALL; transplant survival comparable to international centers.
Treatment Options
Intensive Chemotherapy
Системная терапияПодходит:Acute leukemia, aggressive lymphoma
Технология:Induction and consolidation chemotherapy per protocol
Преимущество:Standard curative approach for acute leukemia
4-6 weeks per cycleFrom $5,000/cycle
Standard protocols at leukemia centersCAR-T Cell Therapy
ИнтервенционныйПодходит:Relapsed/refractory B-cell ALL, lymphoma
Технология:Autologous CAR-T cells (CD19 targeted)
Преимущество:70-80% response rate in relapsed disease
3-4 weeks hospitalizationFrom $50,000
Multiple approved CAR-T products availableAllogeneic Stem Cell Transplant
ИнтервенционныйПодходит:High-risk leukemia, MDS, relapsed lymphoma
Технология:Matched sibling, unrelated, or haploidentical donor
Преимущество:Potentially curative for high-risk disease
30-45 days hospitalizationFrom $50,000
>300 transplants/year at top centersTargeted & Immunomodulatory Therapy
Системная терапияПодходит:CLL, lymphoma, multiple myeloma
Технология:Ibrutinib, venetoclax, lenalidomide, bortezomib
Преимущество:Oral therapy, high efficacy, better tolerated
Daily or weekly, ongoingFrom $300/month
All standard agents availableСвязанные руководства и статьи
Сравнение стоимости
Allogeneic Stem Cell Transplant
US Hospital$350,000
UK Private$250,000
MediLink China$60,000
Save 83% vs US • Includes: donor search, conditioning, transplant, 30-45 day hospitalization, standard post-transplant care
Этапы лечения
1
Diagnosis & Risk Stratification• Week 1-2
- Bone marrow biopsy with flow cytometry
- Cytogenetics and molecular testing
- Imaging for lymphoma (PET-CT)
- HLA typing for transplant consideration
2
Induction Therapy• Month 1-4
- Chemotherapy or targeted therapy
- Response assessment (bone marrow, imaging)
- Donor search (if transplant indicated)
- Supportive care (transfusions, growth factors)
3
Consolidation/Transplant• Month 4-12
- Stem cell transplant (if indicated)
- GVHD prophylaxis and monitoring
- Immune reconstitution
- Long-term follow-up and surveillance
Clinical Outcomes
CAR-T Response Rate
70-80%
B-cell ALL/lymphoma
Transplant 3-Year Survival
60-70%
standard-risk AML
Complete Remission (AML)
70-80%
after induction
Treatment-Related Mortality
<5%
transplant <60 years
Частые вопросы
What is CAR-T cell therapy and is it available in China?
CAR-T is a cellular therapy where patient's T-cells are engineered to target cancer cells. China has multiple approved CAR-T products for B-cell ALL and lymphoma, with 70-80% response rates in relapsed disease.
How do I find a stem cell donor?
Donor search includes: matched sibling (25% chance), unrelated donor registry search, or haploidentical (half-matched) family member. China has large donor registries and extensive haploidentical transplant experience.
What is the success rate of stem cell transplant?
Success varies by disease and risk status. For standard-risk acute leukemia, 3-year survival is 60-70%. For lymphoma in remission, 50-60%. Results at our partner centers match international standards.
What are the main risks of transplant?
Main risks include: graft-versus-host disease (GVHD), infection during immune recovery, organ toxicity from conditioning, and graft failure. Comprehensive supportive care minimizes these risks.
What is stem cell transplant China cost and CAR-T therapy China cost for international patients?
Stem cell transplant China cost is approximately $60,000 (vs $350,000+ in the US). CAR-T therapy China cost for lymphoma or leukemia is approximately $50,000-$65,000 (vs $450,000+ in the US)—both with comparable outcomes at our partner centers.
Ready to Learn More?
Get a personalized treatment plan from our oncology specialists within 48 hours.